There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Medicines Co (MDCO) and ChemoCentryx (CCXI) with bullish sentiments.
Medicines Co (MDCO)
B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Medicines Co today and set a price target of $95.00. The company’s shares closed last Monday at $48.96, close to its 52-week high of $51.93.
According to TipRanks.com, Mamtani has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.5% and a 23.0% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Madrigal Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Medicines Co with a $62.22 average price target, a 23.9% upside from current levels. In a report issued on September 25, Chardan Capital also reiterated a Buy rating on the stock with a $100.00 price target.
See today’s analyst top recommended stocks >>
ChemoCentryx (CCXI)
H.C. Wainwright analyst Edward White maintained a Buy rating on ChemoCentryx today and set a price target of $23.00. The company’s shares closed last Monday at $6.81, close to its 52-week low of $6.16.
According to TipRanks.com, White is a 5-star analyst with an average return of 11.3% and a 45.0% success rate. White covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Inc., Syndax Pharmaceuticals Inc, and Aeglea Biotherapeutics Inc.
ChemoCentryx has an analyst consensus of Strong Buy, with a price target consensus of $18.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
